Antibodies Lecanemab: Alzheimer's Medicine Leqembi Enters the Market From September

Welt

Lean Right

Factuality

Ownership

In Germany, a new Alzheimer's drug is available, with which patients can live healthy for about half a year. Leqembi removes harmful protein deposits in the brain.

Neue Zürcher Zeitung

Lean Right

Factuality

Ownership

For months we have been discussing the benefits and side effects of Leqembi. We have compiled the most important facts for patients.

Zeit Online

Lean Left

Factuality

Ownership

The antibody lecanemab is intended to slow the progression of Alzheimer's in the early stages, but only a small proportion of Alzheimer's patients are eligible for therapy.

spektrum.de

Factuality

Ownership

Lecanemab is intended to help Alzheimer's in the early stages, but not all patients benefit. The antibody medication is expensive – and carries risks.

ikz-online.de

Factuality

Ownership

The drug Leqembi is intended to slow down the course of Alzheimer's dementia. Despite positive studies, there are two major disadvantages at the start of sales.

Deutsches Ärzteblatt

Factuality

Ownership

Berlin – The antibody lecanemab, approved for Alzheimer's therapy, officially launches in Germany today, September 1st. Austria and Germany are the first EU countries where the drug, marketed under the name Leqembi, will be available, announced the participating pharmaceutical companies, Biogen from the USA and Eisai from Japan...